Capricor Therapeutics (CAPR) Revenue (2011 - 2024)

Capricor Therapeutics' Revenue history runs 13 years deep, the most recent figure standing at $11.1 million for Q4 2024.

• On a quarterly basis, Revenue fell 7.92% year-over-year to $11.1 million in Q4 2024; TTM through Sep 2025 was $11.1 million, a 60.7% decrease from a year earlier, with the FY2024 full-year figure at $22.3 million, down 11.55% from the prior year.
• Revenue improved to $11.1 million in Q4 2024 per CAPR's latest filing, from $2.3 million in the prior quarter.
• Across five years, Revenue topped out at $12.1 million in Q4 2023 and bottomed at $16863.0 in Q3 2020.
• The 5-year median for Revenue is $1.9 million (2022), against an average of $3.5 million.
• Across the five-year window, Revenue plunged 88.13% in 2020 and surged 1159.3% in 2023, its largest moves.
• Year by year, Revenue stood at $57830.0 in 2020, then surged by 252.9% to $204082.0 in 2021, then surged by 370.35% to $959903.0 in 2022, then jumped by 1159.3% to $12.1 million in 2023, then slipped by 7.92% to $11.1 million in 2024.
• Per Business Quant, the three latest CAPR Revenue figures stand at $11.1 million (Q4 2024), $2.3 million (Q3 2024), and $4.0 million (Q2 2024).